Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1806
http://purl.obolibrary.org/obo/NCIT_C1806
|
|---|---|
| Preferred Name | Gemtuzumab Ozogamicin |
| Definitions |
A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04) |
|---|---|
| prefLabel | Gemtuzumab Ozogamicin
|
| label | Gemtuzumab Ozogamicin
|
| PDQ_Closed_Trial_Search_ID | 42868
|
| code | C1806
|
| Has_Target | |
| prefixIRI | NCIT:C1806
|
| in_subset |
See more
See less
|
| Display_Name | Gemtuzumab Ozogamicin
|
| Preferred_Name | Gemtuzumab Ozogamicin
|
| FDA_UNII_Code | 8GZG754X6M
|
| Is_PCDC_AML_Permissible_Value_For_Variable | |
| Contributing_Source |
CTRP
FDA
PCDC
|
| Chemical_Formula | C73H96IN6O25S3
|
| Maps_To | Gemtuzumab Ozogamicin
|
| CAS_Registry | 220578-59-6
|
| NSC Number | 720568
|
| NCI_Drug_Dictionary_ID | 42868
|
| Legacy Concept Name | Gemtuzumab_Ozogamicin
|
| type | |
| ALT_DEFINITION | A monoclonal antibody combined with a toxic substance that is used to treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Mylotarg is a type of antibody-drug conjugate.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 42868
|
| Accepted_Therapeutic_Use_For | Acute Myeloid Leukemia.
|
| Semantic_Type |
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C1533699
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |